RxDoctor Payments Data

James Gavin, MD

Nephrology · Trumbull, CTNPI 1609875491

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 63.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $31,932 and has fallen 52.5% since, to $15,163 in 2025. Among nephrology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$103,368in general payments, 2019–2025

Across 153 payments — averaging $675.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$66K
  • Lilly USA, LLC$26K
  • Embecta Corp.$6K
  • Eli Lilly$3K
  • Xeris Pharmaceuticals, Inc.$699
  • Intuity Medical Inc$500
  • plus $758 from 9 others

What the payments were for

  • Consulting fees$50,48049%
  • Speaking & faculty fees$32,28331%
  • Travel & lodging$15,87315%
  • Food & beverage$4,7255%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,368 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.

See all nephrology providers in Connecticut

Medicare billing

Part B allowed, 2024
$193,485
Medicare patients
384
Services billed
1,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate15$4,235
Midodrine Hcl18$2,468
Sevelamer Carbonate16$949
Potassium Citrate ErPotassium Citrate11$485
Carvedilol12$240
Amlodipine Besylate24$218
Tamsulosin Hcl14$169
Metoprolol Succinate15$149
Furosemide26$144
Losartan Potassium15$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$132$4,23515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 nephrology providers in Connecticut.

Other nephrology in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →